Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.

George L. Chen; Paul A. Carpenter; Paul A. Carpenter; Raewyn Broady; Tara K. Gregory; Laura J. Johnston; Barry E. Storer; Jan H. Beumer; Jingxin Qiu; Kiara Cerda; Ryan Le; Joanne M. Otani; Hong Liu; Maureen A. Ross; Sally Arai; Mary E.D. Flowers; Mary E.D. Flowers; Philip L. McCarthy; David B. Miklos

doi:10.1016/J.BBMT.2017.10.021

Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.

George L. Chen
, Paul A. Carpenter
, Paul A. Carpenter
, Raewyn Broady
, Tara K. Gregory
, Laura J. Johnston
, Barry E. Storer
, Jan H. Beumer
, Jingxin Qiu
, Kiara Cerda
, Ryan Le
, Joanne M. Otani
, Hong Liu
, Maureen A. Ross
, Sally Arai
, Mary E.D. Flowers
, Mary E.D. Flowers
, Philip L. McCarthy
, David B. Miklos

Roswell Park Cancer Institute
University of Washington
Fred Hutchinson Cancer Research Center
Department of Medicine, Leukemia BMT Program of British Columbia, Vancouver, British Columbia, Canada
Department of Hematology/Oncology, Colorado Blood Cancer Institute, Denver, Colorado
Stanford University
University of Pittsburgh
Buffalo Medical Group, Buffalo, New York

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Biology of Blood and Marrow Transplantation
Volume	24
Issue number	2
DOIs	https://doi.org/10.1016/J.BBMT.2017.10.021
State	Published - Feb 1 2018
Externally published	Yes

Disciplines

Pharmacology
Medicine and Health Sciences
Gastroenterology
Internal Medicine

Access to Document

10.1016/J.BBMT.2017.10.021License: Unspecified

Cite this

Chen, G. L., Carpenter, P. A., Carpenter, P. A., Broady, R., Gregory, T. K., Johnston, L. J., Storer, B. E., Beumer, J. H., Qiu, J., Cerda, K., Le, R., Otani, J. M., Liu, H., Ross, M. A., Arai, S., Flowers, M. E. D., Flowers, M. E. D., McCarthy, P. L., & Miklos, D. B. (2018). Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 24(2). https://doi.org/10.1016/J.BBMT.2017.10.021

Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. / Chen, George L.; Carpenter, Paul A.; Carpenter, Paul A. et al.
In: Biology of Blood and Marrow Transplantation, Vol. 24, No. 2, 01.02.2018.

Research output: Contribution to journal › Article › peer-review

Chen, GL, Carpenter, PA, Carpenter, PA, Broady, R, Gregory, TK, Johnston, LJ, Storer, BE, Beumer, JH, Qiu, J, Cerda, K, Le, R, Otani, JM, Liu, H, Ross, MA, Arai, S, Flowers, MED, Flowers, MED, McCarthy, PL & Miklos, DB 2018, 'Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.', Biology of Blood and Marrow Transplantation, vol. 24, no. 2. https://doi.org/10.1016/J.BBMT.2017.10.021

@article{161de8815e8e489183d9a74b3a58b26e,

title = "Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.",

author = "Chen, \{George L.\} and Carpenter, \{Paul A.\} and Carpenter, \{Paul A.\} and Raewyn Broady and Gregory, \{Tara K.\} and Johnston, \{Laura J.\} and Storer, \{Barry E.\} and Beumer, \{Jan H.\} and Jingxin Qiu and Kiara Cerda and Ryan Le and Otani, \{Joanne M.\} and Hong Liu and Ross, \{Maureen A.\} and Sally Arai and Flowers, \{Mary E.D.\} and Flowers, \{Mary E.D.\} and McCarthy, \{Philip L.\} and Miklos, \{David B.\}",

note = "Imatinib has clinical activity in chronic graft-versus-host disease (cGVHD), a significant complication of allogeneic hematopoietic cell transplant. Nilotinib is a tyrosine kinase inhibitor that targets the same receptors as imatinib but with different affinities. We tested the hypothesis that nilotinib is safe and has clinical activity in cGVHD.",

year = "2018",

month = feb,

day = "1",

doi = "10.1016/J.BBMT.2017.10.021",

language = "American English",

volume = "24",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1523-6536",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.

AU - Chen, George L.

AU - Carpenter, Paul A.

AU - Broady, Raewyn

AU - Gregory, Tara K.

AU - Johnston, Laura J.

AU - Storer, Barry E.

AU - Beumer, Jan H.

AU - Qiu, Jingxin

AU - Cerda, Kiara

AU - Le, Ryan

AU - Otani, Joanne M.

AU - Liu, Hong

AU - Ross, Maureen A.

AU - Arai, Sally

AU - Flowers, Mary E.D.

AU - McCarthy, Philip L.

AU - Miklos, David B.

N1 - Imatinib has clinical activity in chronic graft-versus-host disease (cGVHD), a significant complication of allogeneic hematopoietic cell transplant. Nilotinib is a tyrosine kinase inhibitor that targets the same receptors as imatinib but with different affinities. We tested the hypothesis that nilotinib is safe and has clinical activity in cGVHD.

PY - 2018/2/1

Y1 - 2018/2/1

UR - http://europepmc.org/abstract/MED/29051021

U2 - 10.1016/J.BBMT.2017.10.021

DO - 10.1016/J.BBMT.2017.10.021

M3 - Article

SN - 1523-6536

VL - 24

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 2

ER -

Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.

Disciplines

Access to Document

Other files and links

Cite this